C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. (Q50578956)

15 March 2018

meta-analysis

0 references

title

C-reactive protein is increased in schizophrenia but is not altered by antipsychotics: meta-analysis and implications. (English)

1 reference

15 March 2018

0 references

0 references

1

1 reference

15 March 2018

Johann Steiner

2

1 reference

15 March 2018

Michael Berk

object named as

M Berk

9

0 references

author name string

H-G Bernstein

3

1 reference

15 March 2018

S Dodd

4

1 reference

15 March 2018

J A Pasco

5

1 reference

15 March 2018

O M Dean

6

1 reference

15 March 2018

P Nardin

7

1 reference

15 March 2018

C-A Gonçalves

8

1 reference

15 March 2018

language of work or name

English

0 references

publication date

14 July 2015

1 reference

15 March 2018

published in

Molecular Psychiatry

1 reference

15 March 2018

volume

21

1 reference

15 March 2018

issue

4

1 reference

15 March 2018

page(s)

554-564

1 reference

15 March 2018

https://scigraph.springernature.com/pub.10.1038/mp.2015.87

exact match

0 references

cites work

Evidence for an immune response in major depression: a review and hypothesis

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Evidence for a dysregulated immune system in the etiology of psychiatric disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

So depression is an inflammatory disease, but where does the inflammation come from?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Serological documentation of maternal influenza exposure and bipolar disorder in adult offspring

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Fetal programming of schizophrenia: select mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Consuming a hypocaloric high fat low carbohydrate diet for 12 weeks lowers C-reactive protein, and raises serum adiponectin and high density lipoprotein-cholesterol in obese subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Association of high-sensitivity C-reactive protein with de novo major depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Elevated C-reactive protein associated with late- and very-late-onset schizophrenia in the general population: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Imbalanced kynurenine pathway in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Kynurenines in CNS disease: regulation by inflammatory cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Association between C-reactive protein and homocysteine with the subcomponents of metabolic syndrome in stable patients with bipolar disorder and schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Inflammation in psychotic disorders: a population-based study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Increased serum interleukin-6 levels in early stages of psychosis: associations with at-risk mental states and the severity of psychotic symptoms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Identification of blood-based molecular signatures for prediction of response and relapse in schizophrenia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Coronary artery disease risk factors in patients with schizophrenia: effects of short term antipsychotic treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Clozapine therapy raises serum concentrations of high sensitive C-reactive protein in schizophrenic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Increased high-sensitivity C-reactive protein levels in Taiwanese schizophrenic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Lifestyle modification and behavior therapy effectively reduce body weight and increase serum level of brain-derived neurotrophic factor in obese non-diabetic patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Prevalence of metabolic syndrome in patients with schizophrenia, and metabolic changes after 3 months of treatment with antipsychotics--results from a German observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Metabolic profile of antipsychotic-naive individuals with non-affective psychosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

C-reactive protein serum level in drug-free male Egyptian patients with schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

C-reactive protein is elevated in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Possible effects of some antipsychotic drugs on C-reactive protein in a drug-naïve psychotic sample

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Chronic risperidone normalizes elevated pro-inflammatory cytokine and C-reactive protein production in omega-3 fatty acid deficient rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Language bias in randomised controlled trials published in English and German.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

The positive and negative syndrome scale (PANSS) for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

A simple method for obtaining original data from published graphs and plots

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Assessing publication bias in meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Quantifying, displaying and accounting for heterogeneity in the meta-analysis of RCTs using standard and generalised Q statistics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Quantitative synthesis in systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Neurovascular unit dysfunction with blood-brain barrier hyperpermeability contributes to major depressive disorder: a review of clinical and experimental evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Ultrastructural damage of capillaries in the neocortex in schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

A systemically-available kynurenine aminotransferase II (KAT II) inhibitor restores nicotine-evoked glutamatergic activity in the cortex of rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Kynurenines in the mammalian brain: when physiology meets pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Targeting kynurenine aminotransferase II in psychiatric diseases: promising effects of an orally active enzyme inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Increased expression of astrocyte markers in schizophrenia: Association with neuroinflammation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Markers of inflammation in the prefrontal cortex of individuals with schizophrenia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Elevated serum levels of the glial marker protein S100B are not specific for schizophrenia or mood disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Decreased peripheral brain-derived neurotrophic factor levels are a biomarker of disease activity in major psychiatric disorders: a comparative meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

A shared framework for the common mental disorders and Non-Communicable Disease: key considerations for disease prevention and control

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differential diagnosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Brain-derived neurotrophic factor as a state-marker of mood episodes in bipolar disorders: a systematic review and meta-regression analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Towards a classification of biomarkers of neuropsychiatric disease: from encompass to compass

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

The concept of staging in bipolar disorder: the role of BDNF and TNF-alpha as biomarkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMP.2015.87

Cardiovascular disease risk in schizophrenia patients: a case control study

21 January 2018

1 reference

12 December 2020

Physical illness in patients with severe mental disorders. II. Barriers to care, monitoring and treatment guidelines, plus recommendations at the system and individual level.

1 reference

12 December 2020

Increased levels of IL-6 in the cerebrospinal fluid of patients with chronic schizophrenia--significance for activation of the kynurenine pathway.

1 reference

12 December 2020

Elevated maternal C-reactive protein and increased risk of schizophrenia in a national birth cohort

1 reference

12 December 2020

Interleukin-6: the missing element of the neurocognitive deterioration in schizophrenia? The focus on genetic underpinnings, cognitive impairment and clinical manifestation.

1 reference

12 December 2020

1 reference

12 December 2020

Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.

1 reference

12 December 2020

Serum levels of IL-6, IL-10 and TNF-α in patients with bipolar disorder and schizophrenia: differences in pro- and anti-inflammatory balance

1 reference

12 December 2020

[Changes of the level of serum antibodies to neuroantigens in patients with schizophrenia during the treatment]

1 reference

12 December 2020

Association of blood levels of C-reactive protein with clinical phenotypes in Arab schizophrenic patients

1 reference

12 December 2020

S100B expression in and effects on microglia

1 reference

12 December 2020

Childhood maltreatment is associated with increased body mass index and increased C-reactive protein levels in first-episode psychosis patients.

1 reference

12 December 2020

Aging-associated inflammation in healthy Japanese individuals and patients with Werner syndrome

1 reference

12 December 2020

Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications.

1 reference

12 December 2020

Identifiers

DOI

10.1038/MP.2015.87

1 reference

15 March 2018

PubMed ID

26169974

1 reference

15 March 2018